Skip to main content
Equibles
QURE logo

QURE · uniQure N.V.

Track QURE — free

Use QURE with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about QURE

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$48.62 +1.56 (+3.31%) At close · Aug 14
Market Cap
$3.07B
Shares
63.07M

uniQure N.V. Earnings Call Transcripts

Every quarterly earnings call for uniQure N.V. (QURE) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼38% $1.53M '20 Q2 20-07-31 ▼99.9% $497,000 '22 Q2 22-08-08 ▼81.5% $1.57M −$43.64M '25 Q1 25-05-09 ▼52.7% $5.26M −$37.72M '25 Q2 25-07-29 ▲61.8% $3.70M −$80.53M '25 Q3 25-11-10 ▲6.6% $5.57M −$37.09M '25 Q4 26-03-02 LATEST ▲127.3% $3.56M −$53.53M '26 Q1 26-05-05
Earnings call
FY26 · Q2
2026-07-29
uniQure N.V. Q2 FY2026 Earnings Call
Confident tone AMT-130 Huntington's disease regulatory progress AMT-130 long-term clinical data FDA confirmatory trial design
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-05
uniQure N.V. Q1 FY2026 Earnings Call
Balanced tone AMT-130 in Huntington's disease UK MHRA submission UK commercial readiness and access
Revenue
$3.56M
▲ 127.3% YoY
Diluted EPS
$-0.85
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-02
uniQure N.V. Q4 FY2025 Earnings Call
Cautious tone FDA feedback on regulatory path for AMT-130 Phase III sham-controlled study requirement External comparator from natural history data
Revenue
$5.57M*
▲ 6.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-10
uniQure N.V. Q3 FY2025 Earnings Call
Cautious tone FDA pre-BLA feedback and regulatory uncertainty AMT-130 Huntington's disease pivotal data Ex-U.S. regulatory strategy
Revenue
$3.70M
▲ 61.8% YoY
Diluted EPS
$-1.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
uniQure N.V. Q2 FY2025 Earnings Call
Confident tone AMT-130 pivotal data and regulatory progress Huntington's disease competitive positioning BLA readiness and manufacturing (PPQ/CMC)
Revenue
$5.26M
▼ 52.7% YoY
Diluted EPS
$-0.69
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-09
uniQure N.V. Q1 FY2025 Earnings Call
Confident tone AMT-130 Huntington's program and BLA pathway Regulatory designations and FDA interactions Pipeline expansion across other gene therapy programs
Revenue
$1.57M
▼ 81.5% YoY
Diluted EPS
$-0.82
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
uniQure N.V. Q2 FY2022 Earnings Call
Revenue
$497,000
▼ 99.9% YoY
Diluted EPS
$-0.84
▼ 109.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-31
uniQure N.V. Q2 FY2020 Earnings Call
Revenue
$1.53M
▼ 38% YoY
Diluted EPS
$-0.96
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–8 of 8 earnings calls
Key facts CIK 1590560 CUSIP N90064101 13F (30d) 256 filings 248 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)